Pharma & Healthcare – Pfizer chansing AstraZeneca, FDA okays start of BrainStorm stem cell trial in ALS patients and more.
Pfizer chasing AstraZeneca for potential $100 billion deal by Ben Hirschler Published on Reuters
U.S. drugmaker Pfizer Inc is working on its next move in a potential $100 billion battle for Britain’s AstraZeneca Plc after having two bids rejected, as deal-making grips the healthcare industry… [ Read More ]
The Three Questions Pfizer Must Answer About Its $99 Billion AstraZeneca Bid by Matthew Herper Published on Forbes
This morning, Pfizer confirmed that it had asked AstraZeneca to consider a merger, and been rebuffed. Under U.K. law, it had to disclose the offer and went public with a $98.7 billion offer to buy the London-based drug maker… [ Read More ]
FDA okays start of BrainStorm stem cell trial in ALS patients by Tova Cohen Published on Reuters
BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration approved the start of a mid-stage clinical trial of its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS)…[ Read More ]
Live Industry News
Follow @ACI_Pharma & @ACI_Health
Join ACI Pharmaceuticals/Biotech/Life Sciences Experts Group
Join ACI Healthcare: Legal, Regulatory, and Compliance Experts Group
Related Event
For the complete list of all Pharma upcoming events: Click Here
For the complete list of all Healthcare upcoming events: Click Here
To download past Pharma conference materials: Click Here
To download past Healthcare conference materials: Click Here